report earn coverag
even announc partnership bgne
revenu guidanc primarili
expect weak recoveri rebound
see major disrupt payor increas
roctavian valrox pdufa still aug track expect
ema delay decis late may
follow data readout delay new steroid
pku gene therapi delay due covid start dose
monitor covid start vosoritid diss
discount rate reflect lower r/f
rate termin growth fall net
impact pt
rais revenu guidanc vs
current run rate higher mid-point
rais guidanc note compliance/persist
may factor rest year
studi paus due covid
process re-initi screening/enrol
data timelin tbd
launch lower discount rate
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
reflect lower r/f rate net effect pt increas
partner bgne develop igm
iga antibodi expect clinic
actual start infecti diseas effort
grant gate foundat abil select
plasmablast high affin pathogen
differenti approach identifi
doesnt plan divert oncolog id beyond
worth note valuat
antivir antibodi effort valu higher
deriv valuat base dcf model use
discount rate appli commerci stage biotech
compani premium termin growth rate somewhat gener
given high expens estim consid highli durabl
asset naglazym vimizim brineura addit freshli emerg
pipelin particular valrox vosoritid
face develop regulatori commerci risk brineura batten
sale may meet investor expect especi longer term follow fail
show compel surviv advantag pegvalias pku foreign protein
experi date surprisingli benign may still caus
clinic side effect off-set benefit hemophilia result
date excit impress gene therapi new platform risk
fulli character vosoritid achondroplast dwarfism result
phase far definit compani present enough data
high degre confid phase trial may also
emerg threat compani establish portfolio therapi one
compani given meaning credit pipelin
develop stumbl particularli impact share
deriv pt dcf use termin growth rate
ex-u reimburs cystic fibrosi product price pressur market
valuat price deriv dcf
includ termin valu base discount rate reflect early-
stage natur bcel program termin growth rate repres
continu growth compani pipelin
risk bcel valuat depend upon clinic success pipelin
program focu oncolog competit space
need differenti number player compani
present compel preclin data find may translat clinic
result compani current financ requir subsequ equiti rais
articl articl
time dissemin april pm et
analyst josh schimmer angela ni maneka mirchandaney primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
